Abstracts tagged "juvenile dermatomyositis and juvenile myositis"

Abstract Number: 2341 • 2017 ACR/ARHP Annual Meeting
The Interaction between Genetic Risk Factors and Age of Disease Onset in Juvenile Dermatomyositis
Claire Deakin¹, John Bowes², Lucy Marshall¹, Cerise Johnson¹, Gulnara Mamyrova³, Rodolfo Curiel⁴, Kelly A. Rouster-Stevens⁵, Heinrike Schmeling⁶, Adam Huber⁷, Brian M. Feldman⁸, Ann M Reed⁹, Lauren M. Pachman¹⁰, Soumya Raychaudhuri¹¹, Stephen Eyre¹² and Lucy R Wedderburn¹, ¹Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, ²Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ³Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Department of Rheumatology, George Washington University, Washington, DC, ⁵Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁶Alberta Children’s Hospital/University of Calgary, Calgary, AB, Canada, ⁷IWK Health Centre, Halifax, NS, Canada, ⁸Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹Rheumatology, Duke University, Durham, NC, ¹⁰Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹¹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, severe autoimmune disease characterized by muscle weakness and rash. Clinical features of JDM are heterogeneous, and can include…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].